SCHEMBL3740795

SCHEMBL3740795

C[Si](C)(C)C(NC(=O)O)c1cccc2c1Cc1ccccc1-2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HTR2B P41595 2/20 0.39
HTR7 P34969 1/20 0.39
PNMT P11086 1/20 0.36
CTSA P10619 7/20 0.35
SRD5A2 P31213 1/20 0.35
CYP1A2 P05177 1/20 0.35
ADRA2A P08913 1/20 0.35
MAOA P21397 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR2C P28335 1/20 0.35
SLC6A4 P31645 1/20 0.35
GSR P00390 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
RRM1 P23921 1/20 0.35
RRM2B Q7LG56 1/20 0.35
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21758208 0.75 NPC1 (0.47) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL9420910 0.75 NPC1 (0.50) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL2938541 0.74 RAB9A (0.42) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL21046174 0.74 HTR2B (0.49) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL1567105 0.74 RAB9A (0.50) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL21443923 0.72 NPC1 (0.48) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL1567119 0.72 NPC1 (0.50) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL8197052 0.72 HTR7 (0.47) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL30533158 0.71 NPC1 (0.47) NPC1RAB9AHTR2BHTR7PNMT
SCHEMBL21436821 0.71 NPC1 (0.47) NPC1RAB9AHTR2BHTR7PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292163-A1 Antitumoral Compounds PHARMA MAR, S.A. (ES) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292163-A1 Antitumoral Compounds TP53, XPO1, TOP2B NPC1 655/4885RAB9A 1796/4885HTR2B 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.